Author Archives: clinicalaccelerator

Referring physicians: the overlooked resource for faster patient enrolment

It is widely known and understood that the no. 1 cause of delays in clinical trials is inefficient patient enrolment. The problem has become widespread and does not show any signs of abating. According to a TUFTS analysis, 48% of … Continue reading

Posted in ClinAccel.Net, Clinical Accelerator, Cost of Clinical Trials, Patient Enrolment | Leave a comment

Why do rare disease clinical trials face greater challenges and what are some solutions?

Over 6,800 rare diseases such as Haemophilia, Tay Sach’s disease and Gaucher disease are affecting more than 25 million Americans. Still yet, there is limited understanding or knowledge of these debilitating, life threatening and progressive diseases. The Orphan Drug Act … Continue reading

Posted in Patient Enrolment, Rare Diseases | Leave a comment

Clinical Accelerator forms ClinAccel.Net

Clinical Accelerator forms ClinAccel.Net, a dedicated division focusing on expanding a network of partnering clinical research sites, and fast and efficient patient enrolment into clinical studies Douglas, February 28, 2017 – Clinical Accelerator, a clinical contract research organization with operations … Continue reading

Posted in Clinical Accelerator, Feasibility Assessment, Patient Enrolment | Leave a comment

Find FDA Documents by Name, Text and Other Keywords

OpenTrialsFDA works on making clinical trial data from the FDA (the US Food and Drug Administration) more easily accessible and searchable. Until now, this information has been hidden in the user-unfriendly Drug Approval Packages that the FDA publishes via its … Continue reading

Posted in FDA | Leave a comment

The EMA and Foreign Data_Part 2

Previously we looked at data from the European Medicines Agency, which showed the increasing role since 2005 that some ‘Rest of the World’ nations were playing in enrolling patients in clinical trials supplying pivotal data for marketing authorisation applications (MAAs) … Continue reading

Posted in EMA, European Union, Regulations | Leave a comment

The EMA and Foreign Data_Part 1

In recent years we have seen an increase in the number of trials conducted for EU marketing authority applications (MAA) in areas other than what was considered to be in the two main European [European Union (EU) / European Economic … Continue reading

Posted in EMA, European Union, Regulations | Leave a comment

Regulatory Approval Received for VAL401 in Phase IIB Clinical Trial in Georgia

Below, we are re-publishing with permission the press-release issued by ValiRx on August 11, 2016 London, UK., 11 August 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for … Continue reading

Posted in Clinical Accelerator | Leave a comment

Noxopharm Provides Update on Inaugural Clinical Study

Below, we are re-publishing with permission the press-release issued by Noxopharm on August 10, 2016 Noxopharm has completed putting in place the required logistics to enable it to conduct a clinical study of its lead pipeline drug candidate, NOX66, in Europe, commencing … Continue reading

Posted in Clinical Accelerator | Leave a comment

Brexit and Clinical Trials_Part 2

What are the implications and consequences of the Brexit vote for the pharmaceutical and MedTech industries so close to the heart of most reading this piece? Many in these industries and in academic research establishments argued that a Brexit vote … Continue reading

Posted in European Union | Leave a comment

Brexit and Clinical Trials_Part 1

Well, the people of Britain have now spoken – albeit not that clearly given a 51.9%:48.1% split in the referendum voting figures. Nevertheless, it’s a democratic decision and now the word on almost everyone’s lips is “Brexit”. Despite a protest … Continue reading

Posted in European Union, Uncategorized | Leave a comment